Indolin-2-one derivatives
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsToru Esaki, Takashi Emura, Eiichi Hoshino
Life of this patent
Estimating the term…
Loading patent…
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsToru Esaki, Takashi Emura, Eiichi Hoshino
Estimating the term…
A compound represented by formula (I): wherein R1 represents a halogen atom, a lower alkyl group, a lower alkoxy group, a hydroxyl group, a nitro group, a trifluoromethyl group, a lower alkylthio group, an acyl group, a carboxyl group, a mercapto group or an amino group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, an alkoxy group, an acyl group, an aryl group or a heterocyclic group; R3 represents a lower alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; R4 represents a hydrogen atom, a lower alkyl group, an aryl group, a heterocyclic group, —OR5, —SR5 or —NR6R7 (wherein R5, R6, and R7 each represent a lower alkyl group, etc.); X and Y each represent —CH2—, —NH— or —O—; and n represents an integer of from 0 to 4, and an intermediate for synthesis thereof are disclosed. The compound of the present invention exhibits selective antagonism against gastrin receptors without causing side effects attributed to CCK-A receptor antagonism and is useful for the treatment and prevention of peptic ulcers, gastritis, reflux esophagitis, and Zollinger-Ellison syndrome, and for the treatment of neoplasm originating in the gastrointestinal system.
A compound represented by formula (I):
Dependencies are inferred from the claim text.